This report was first published by Endpoints News. To see the original version, click here
It’s becoming Hengrui Pharma’s world, and some Western drugmakers are just living in it.
China’s largest pharma company, which boasts one of the biggest pipelines in the industry, has lined up Bristol Myers Squibb as its latest partner in a deal worth up to $15.2 billion. The total value of the Tuesday pact marks one of the largest East-to-West cross-border deals in industry history.
您已阅读13%（475字），剩余87%（3096字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。